Loading the company…
Loading the company…
Families: Incontinence, prolapse & sacral neuromodulation.
All companies · Product and company coverage
In the last ten years FDA made 1 decision for Rigicon (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2019 (1). The latest was on 2019-04-15.
| Family | Decisions on record |
|---|---|
| Incontinence, prolapse & sacral neuromodulation | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2019-04-15 | 510(k) | K181673 | Rigi10 Malleable Penile Prosthesis |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Rigicon.
In 2025, Rigicon reported engagement with 7 surgeons and other clinicians in the states MedaRep covers, worth $1,586 in consulting, speaking, meals and travel for its device products, the most in Florida ($684 to 1). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($684, 1 engaged), Maryland ($682, 4 engaged), New York ($120, 1 engaged), California ($100, 1 engaged).